The global antihypertensive drugs market size reached US$ 29.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 38.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.78% during 2023-2032. The increasing prevalence of hypertension, rising number of patients suffering from CVDs, and the growing number of clinical studies represent some of the key factors driving the market.
Antihypertensive drugs are utilized to treat hypertension wherein the force of blood against the walls of the arteries becomes high and can increase the risk of heart disease, stroke, and other health problems. They generally comprise diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and vasodilators.
They work by relaxing the blood vessels, reducing the amount of fluid in the blood vessels, and decreasing the amount of hormones that cause blood vessels to constrict. They also slow down the heartbeat, maintain a healthy systolic BP, improve life expectancy, and minimize the risk of premature death. At present, key players are introducing imidazolines, monatepil, and neutral endopeptidase inhibitors to expand their product portfolio.
This, coupled with the rising number of clinical studies and trials to develop new treatments for hypertension, is strengthening the growth of the market. Furthermore, the growing usage of over the counter (OTC) drugs to treat BP-related diseases on account of expanding healthcare costs is creating a positive outlook for the market. Besides this, there is a rise in the number of online retail platforms that offer antihypertensive drugs according to the dosage needed by the consumer. This, along with significant growth in the pharmaceutical and e-commerce industries, is propelling the growth of the market. Additionally, the increasing adoption of health insurance policies that provide financial assistance for hypertension treatment and minimize healthcare expenses is impelling the growth of the market.
Some of the companies covered include AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Antihypertensive drugs are utilized to treat hypertension wherein the force of blood against the walls of the arteries becomes high and can increase the risk of heart disease, stroke, and other health problems. They generally comprise diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and vasodilators.
They work by relaxing the blood vessels, reducing the amount of fluid in the blood vessels, and decreasing the amount of hormones that cause blood vessels to constrict. They also slow down the heartbeat, maintain a healthy systolic BP, improve life expectancy, and minimize the risk of premature death. At present, key players are introducing imidazolines, monatepil, and neutral endopeptidase inhibitors to expand their product portfolio.
Antihypertensive Drugs Market Trends:
The surging prevalence of hypertension and high BP among individuals represents one of the major factors driving the demand for antihypertensive drugs around the world. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is influencing the market positively. In addition, the increasing number of patients suffering from cardiovascular diseases (CVDs) on account of sedentary lifestyles, unhealthy dietary patterns, high-stress levels, diabetes, and obesity among the masses is favoring the growth of the market. Apart from this, governing agencies of numerous countries are initiating campaigns to spread awareness about the hypertension disorder, its symptoms, diagnosis, and treatment.This, coupled with the rising number of clinical studies and trials to develop new treatments for hypertension, is strengthening the growth of the market. Furthermore, the growing usage of over the counter (OTC) drugs to treat BP-related diseases on account of expanding healthcare costs is creating a positive outlook for the market. Besides this, there is a rise in the number of online retail platforms that offer antihypertensive drugs according to the dosage needed by the consumer. This, along with significant growth in the pharmaceutical and e-commerce industries, is propelling the growth of the market. Additionally, the increasing adoption of health insurance policies that provide financial assistance for hypertension treatment and minimize healthcare expenses is impelling the growth of the market.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutic class, type and distribution channel.Therapeutic Class Insights:
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others
Type Insights:
- Primary Hypertension
- Secondary Hypertension
Distribution Channel Insights:
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global antihypertensive drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.Some of the companies covered include AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global antihypertensive drugs market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global antihypertensive drugs market?
- What is the impact of each driver, restraint, and opportunity on the global antihypertensive drugs market?
- What are the key regional markets?
- Which countries represent the most attractive antihypertensive drugs market?
- What is the breakup of the market based on the therapeutic class?
- Which is the most attractive therapeutic class in the antihypertensive drugs market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the antihypertensive drugs market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the antihypertensive drugs market?
- What is the competitive structure of the global antihypertensive drugs market?
- Who are the key players/companies in the global antihypertensive drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Antihypertensive Drugs Market
6 Market Breakup by Therapeutic Class
7 Market Breakup by Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company Limited
- Johnson & Johnson Services Inc.
- Lupin Pharmaceuticals Inc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 143 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 29.7 Billion |
| Forecasted Market Value ( USD | $ 38 Billion |
| Compound Annual Growth Rate | 2.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
